Shots:
- Viridian & Kissei have entered into an exclusive collaboration & license agreement to develop & commercialize veligrotug & VRDN-003 in Japan
- As per the deal, Kissei will secure an exclusive license to develop & commercialize veligrotug & VRDN-003 in Japan, with the responsibility of all development, regulatory, & commercialization activities, & related costs in exchange for $70M upfront & ~$315M in development, regulatory, & commercial milestones, with net sales-based tiered royalties (20s to mid-30s%)
- Veligrotug is being evaluated in global P-III (THRIVE & THRIVE-2) trials for chronic TED & VRDN-003 (SC) will advance to P-III (REVEAL-1 & 2) trials for the treatment of active & chronic TED
Ref: Businesswire| Image: Viridian | Press Release
Related News:- Viridian Therapeutics Releases the Long-Term Durability Data Evaluating Veligrotug in P-III (THRIVE) Study in Active TED
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
